Tetrahydrobiopterin: a novel antihypertensive therapy
Authors:
- 6 March 2008
- journal article
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 22 (6) , 401-407
Abstract
Tetrahydrobiopterin (BH4) is a cofactor for the nitric oxide (NO) synthase enzymes, such that its insufficiency results in uncoupling of the enzyme, leading to release of superoxide rather than NO in disease states, including hypertension. We hypothesized that oral BH4 will reduce arterial blood pressure (BP) and improve endothelial function in hypertensive subjects. Oral BH4 was given to subjects with poorly controlled hypertension (BP >135/85 mm Hg) and weekly measurements of BP and endothelial function made. In Study 1, 5 or 10 mg kg−1 day−1 of BH4 (n=8) was administered orally for 8 weeks, and in Study 2, 200 and 400 mg of BH4 (n=16) was given in divided doses for 4 weeks. Study 1: significant reductions in systolic (P=0.005) and mean BP (P=0.01) were observed with both doses of BH4. Systolic BP was 15±15 mm Hg (P=0.04) lower after 5 weeks and persisted for the 8-week study period. Study 2: subjects given 400 mg BH4 had decreased systolic (P=0.03) and mean BP (P=0.04), with a peak decline of 16±19 mm Hg (P=0.04) at 3 weeks. BP returned to baseline 4 weeks after discontinuation. Significant improvement in endothelial function was observed in Study 1 subjects and those receiving 400 mg BH4. There was no significant change in subjects given the 200 mg dose. This pilot investigation indicates that oral BH4 at a daily dose of 400 mg or higher has a significant and sustained antihypertensive effect in subjects with poorly controlled hypertension, an effect that is associated with improved endothelial NO bioavailability.Keywords
This publication has 32 references indexed in Scilit:
- High-dose oral vitamin C partially replenishes vitamin C levels in patients with Type 2 diabetes and low vitamin C levels but does not improve endothelial dysfunction or insulin resistanceAmerican Journal of Physiology-Heart and Circulatory Physiology, 2006
- Avoiding Papillary Muscle Infarction With Myocardial Contrast Echocardiographic Guidance of Nonsurgical Septal Reduction Therapy for Hypertrophic Obstructive CardiomyopathyCirculation, 2004
- Interactions of Peroxynitrite, Tetrahydrobiopterin, Ascorbic Acid, and ThiolsJournal of Biological Chemistry, 2003
- Tetrahydrobiopterin Improves Endothelium-Dependent Vasodilation in Chronic SmokersCirculation Research, 2000
- Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats.Journal of Clinical Investigation, 1998
- Role of Superoxide in Angiotensin II–Induced but Not Catecholamine-Induced HypertensionCirculation, 1997
- Tetrahydrobiopterin restores endothelial function in hypercholesterolemia.Journal of Clinical Investigation, 1997
- Tetrahydrobiopterin and Dysfunction of Endothelial Nitric Oxide Synthase in Coronary ArteriesCirculation, 1995
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993
- The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholineNature, 1980